Agenus Inc (AGEN) 6.14 $AGEN Antigenics Up 53.8% Since

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2016 at 3:21 AM

Agenus Inc (AGEN) 6.14 $AGEN

Antigenics Up 53.8% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Wed Aug 31, 12:16AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 53.77% as of today's recent price of $6.42.
AGEN: 6.14 (-0.05)

Uptrend Call Working As Antigenics Stock Rises 45.4% (AGEN)
Comtex SmarTrend(R) - Tue Aug 23, 12:43PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 3 months, Antigenics has returned 45.39% as of today's recent price of $6.07.
AGEN: 6.14 (-0.05)

Why Agenus (AGEN) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Agenus (AGEN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
AGEN: 6.14 (-0.05)

Research Report Initiation on Biotech Stocks -- Agenus, ProNAi Therapeutics, Vanda Pharma, and Genocea Biosciences
PR Newswire - Thu Aug 11, 7:40AM CDT
This morning on Stock-Callers.com we have Biotech industry under review. This segment is focused on new drug developments and clinical researches. Stocks under evaluation are: Agenus Inc. (NASDAQ: AGEN), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Genocea Biosciences Inc. (NASDAQ: GNCA). Learn more about these stocks by downloading their free report at:
AGEN: 6.14 (-0.05), VNDA: 15.55 (+0.26), GNCA: 5.37 (+0.09), DNAI: 1.81 (unch)

Antigenics Has Returned 48.7% Since SmarTrend Recommendation (AGEN)
Comtex SmarTrend(R) - Mon Aug 08, 12:44PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 48.74% as of today's recent price of $6.21.
AGEN: 6.14 (-0.05)

Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:32AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.76.
AGEN: 6.14 (-0.05), BIIB: 313.59 (+7.56), ICPT: 150.74 (+3.92)

Will Agenus (AGEN) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:27AM CDT
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN)
AGEN: 6.14 (-0.05)

Geron (GERN) Posts Narrower-Than-Expected Loss in Q2
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 9:04AM CDT
Investor focus will remain on Geron's (GERN) progress with the development of imetelstat.
AGEN: 6.14 (-0.05), JNJ: 119.32 (+0.24), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02)

Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Aerie (AERI) posted a wider-than-expected loss of 87 cents in the second-quarter 2016 loss.
AGEN: 6.14 (-0.05), ANIP: 59.86 (-1.56), AERI: 19.60 (+0.39), ANIK: 47.89 (-0.05)

Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:35AM CDT
Abeona Therapeutics Inc. (ABEO) was a big mover last session, as the company saw its shares rise around 6% on the day.
AGEN: 6.14 (-0.05), ABEO: 4.47 (+0.18)

Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 6.14 (-0.05), ANIP: 59.86 (-1.56), MRK: 62.98 (+0.08), NKTR: 18.45 (+0.34)

Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Agenus (AGEN) reported a loss of 24 cents in second-quarter of 2016, lower than the Zacks Consensus Estimate of 34 cents.
AGEN: 6.14 (-0.05)

Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Jul 28, 7:49AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
AGEN: 6.14 (-0.05)

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
BusinessWire - Wed Jun 22, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.
AGEN: 6.14 (-0.05)

Agenus to Present at the 2016 JMP Securities Life Sciences Conference
BusinessWire - Wed Jun 15, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference will take place at the St. Regis New York in New York City.
AGEN: 6.14 (-0.05)

Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 6.14 (-0.05), MRK: 62.98 (+0.08)

Agenus to Webcast Annual Meeting of Stockholders
BusinessWire - Wed Jun 08, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
AGEN: 6.14 (-0.05)

Agenus to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 9:30am ET.
AGEN: 6.14 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vetology Reinvents AI Models for Veterinary Radiology

Revamping AI in Veterinary Practices Out there in San Diego, Vetology's been rolling up its sleeves and getting down to brass tacks with a complete do-over of their AI classifiers. They’ve rebuilt all 94 of them, every last one, on a brand-new architecture. No small task, this overhaul stretched from June to August and it wasn't just paint and polish but a whole new...

IRS Views Challenge Tax-Engineered Healthcare Schemes

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...

Debt Crisis Looms: Social Security at Risk

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

Bascom's Strategic Play on a Dallas Apartment Deal

Unpacking Bascom's Jasmine Acquisition In a market that's been more slippery than a greased pig, Bascom Group's move buying up Jasmine Apartments is capturing some eyes. Situated in North Dallas, this 370-unit complex ain't just another brick in the wall—it's Bascom's 42nd entry into Texas, reinforcing their knack for sniffing out deals others might tiptoe around,...

AI Ambassadors Rethink Arbitration's Future

Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...

DAHON's Tech: Crafting Folders That Ride Like Road Bikes

The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...

Digital Wine Atlas Maps 4.3 Million Vineyards Globally

Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...

Celebrate National Service Dog Month with Canine Companions

A Month to Celebrate Unseen Heroes Take a pause. We're talking about National Service Dog Month. What in the world could be more endearing than a pack of puppies, those hopeful bundles of joy, destined to grow up and play pivotal roles in people's lives? Canine Companions is rolling out the red carpet for these future heroes, with a nine-day Puppy Cam event from September...

Sierra Ridge Advisors Join Gateway Financial Milestone

Big Moves in the Financial Advisory World Let's dive right in. Here's a real shakeup in the advisory realm: 28 financial advisors and team members from Sierra Ridge Advisor Group are packing their bags for Gateway Financial Partners. We're talking about a significant shift involving $825 million in assets under advisement. Instead of sticking with Sierra Ridge as it...

Crimson Coward's Cheez Nugs Shake Up Fast-Casual Scene

New Kid on the Block: Cheez Nugs Buckle up folks, Crimson Coward is at it again. They're rolling out something they claim will blow your taste buds straight out of the water: Cheez Nugs. Dropping nationwide on September 18, 2026, these aren't your run-of-the-mill cheese bites. We're talking 100% whole-milk mozzarella, a golden herb-seasoned crust, and a mouthful of creamy...